脑胶质瘤患者自体免疫治疗前后T细胞亚群的变化

 目的 探讨脑胶质瘤患者自体免疫治疗的临床应用，观察该治疗对T细胞亚群水平的影响。方法 试验组21例脑胶质瘤患者接受自体树突状细胞免疫治疗，对照组19例接受常规治疗，进行临床随访并检测两组T细胞亚群水平的变化。结果 试验组中位生存时间（29个月）远大于对照组（10个月），两组生存曲线分布差异有显著性意义（P〈0．05）。脑胶质瘤患者外周血中CD^3＋含量、CD^4＋含量以及CD^4＋／CD^8＋比值明显低于正常对照组（P〈0．01），免疫治疗后患者外周血CD^3＋、CD^4＋、CD^8＋含量以及CD^4＋／CD^8＋比值与对照组比较均增加（P〈0．05），但CD^4＋／CD^8＋比值仍低于健康成人组（P〈0．05）。结论 脑胶质瘤存在免疫功能抑制，自体树突状细胞肿瘤疫苗治疗可一定程度重建、增强机体肿瘤免疫应答，抑制脑胶质瘤的复发和进展，从而有效地延长脑胶质瘤患者的生存时间。

Alterations of T Cell Subpopulation in Glioma Patients Received Autologous Immunotherapy

Objective To evaluate the clinical application of autologous dendritic tumor vaccination on brain glioma, and to access the alterations of T cell subpopulation in patients with brain glioma before and after autologous immunotherapy. Methods The experimental group (21 Glioma patients) received vaccinations of autologous dendritic cell pulsed with autologous tumor peptides, while the control group (19 glioma patients) only received the regular treatments. Following-ups were carried out and the T cell subpopulations were measured. Results The median survival time of the experimental group (29 months) was significantly longer than that of control group (10 month) (P< 0.05). The levels of CD3 + and CD4 + and the ratio of CD4 +/CD8 + ratio in peripheral blood in glioma patients were significantly lower compared with the healthy control, the levels of CD3 +, CD4 +, CD8 +and the CD4 +/CD8 + ratio were significantly increased after immunotherapy than before, but the CD4 +/CD8 + ratio remained lower compared with the healthy control. Conclusion The immune functions of glioma patients were suppressed. Immunotherapy could prolong the survival time of the glioma patient by reconstructing and enhancing some parts of the tumor immunity.